share_log

Philip (Phil) Powell Acquires 20,000 Shares of INOVIQ Ltd (ASX:IIQ) Stock

Philip (Phil) Powell Acquires 20,000 Shares of INOVIQ Ltd (ASX:IIQ) Stock

菲利普(菲爾)鮑威爾收購 INOVIQ 有限公司(ASX:IIQ)股票的 20,000 股
Financial News Live ·  2023/03/10 10:53

INOVIQ Ltd (ASX:IIQ – Get Rating) insider Philip (Phil) Powell bought 20,000 shares of the firm's stock in a transaction on Monday, March 6th. The stock was acquired at an average cost of A$0.57 ($0.38) per share, with a total value of A$11,400.00 ($7,651.01).

INOVIQ 有限公司 (ASX: IIQ — 獲得評級) 內幕菲利普 (菲爾) 鮑威爾買了 20,000 股該公司的股票在交易上週一, 3 月 6 日.收購該股票的平均成本為每股 0.57 澳元(0.38 美元),總價值為 11,40 澳元(7,651.01 美元)。

Philip (Phil) Powell also recently made the following trade(s):

菲利普(Phil)鮑威爾最近還進行了以下交易:

Get
取得
INOVIQ
INOVIQ
alerts:
警報:
  • On Wednesday, March 1st, Philip (Phil) Powell purchased 18,518 shares of INOVIQ stock. The shares were acquired at an average cost of A$0.54 ($0.36) per share, with a total value of A$9,999.72 ($6,711.22).
  • On Friday, March 3rd, Philip (Phil) Powell purchased 19,481 shares of INOVIQ stock. The shares were acquired at an average cost of A$0.56 ($0.38) per share, with a total value of A$10,909.36 ($7,321.72).
  • 3 月 1 日星期三,菲利普(菲爾)鮑威爾購買了 18,518 股 INOVIQ 股票。這些股份的平均成本為每股 0.54 澳元(0.36 美元),總價值為 9,999.72 澳元(6,711.22 美元)。
  • 3 月 3 日(星期五),菲利普(菲爾)鮑威爾購買了 19,481 股 INNOVIQ 股票。這些股份的平均成本為每股 0.56 澳元(0.38 美元),總價值為 10,909.36 澳元(7,321.72 美元)。

INOVIQ Stock Performance

益威科技股票表現

The company has a debt-to-equity ratio of 3.73, a current ratio of 5.28 and a quick ratio of 9.52.

該公司的債務與權益比率為 3.73,流動比率為 5.28,快速比率為 9.52。

About INOVIQ

關於我們

(Get Rating)

(取得評分)

INOVIQ Ltd engages in the research, development, and commercialization of diagnostic and exosome-based products to enhance the diagnosis and treatment of cancer and other diseases in Australia and the United States. The company offers hTERT test, an immunocytochemistry test used as an adjunct to urine cytology testing for bladder cancer; and EXO-NET for capturing and isolating exosomes from liquid biopsy sample.

INOVIQ Ltd 從事診斷和外出體產品的研究,開發和商業化,以加強澳大利亞和美國癌症和其他疾病的診斷和治療。該公司提供 hTert test,這是一種免疫細胞化學 test,用作膀胱癌尿細胞學測試的輔助性測試;EXO-NET 用於從液體活檢樣本中捕獲和隔離外泌體。

Featured Stories

特色故事

  • FuelCell Energy Gains Traction, Shares Surge
  • Solo Brands May Remind Investors Why Cash is King
  • Someone Is Buying The Dip In MongoDB
  • Cameco: Is the New Uranium Bull Market Here to Stay?
  • Etsy Stock: Crafty Bargain or Piece of Junk?
  • 燃料電池能源獲得牽引力,股票激增
  • 獨奏品牌可能會提醒投資者為何現金為王
  • 有人正在購買 MongoDB 的浸泡
  • Cameco: 新鈾牛市會留在這裡嗎?
  • Etsy 股票:狡猾的討價還價還是一塊垃圾?

Receive News & Ratings for INOVIQ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INOVIQ and related companies with MarketBeat.com's FREE daily email newsletter.

接收 INOVIQ 每日最新消息和評分 -在下面輸入您的電子郵件地址,以通過 MarketBeat.com 的免費每日電子郵件通訊接收 INOVIQ 和相關公司的最新新聞和分析師評級的簡要每日摘要。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論